Metadata
Dataset ID:
10
Study Design
| Study Design Background | To investigate if ultrasound-mediated blood-brain barrier opening or drug formulation in polymetic nanoparticles can increase the acuumulation of cabazitazel in the brain or theapeutic effect for glioblastoma. |
|---|---|
| Study Description | FUS for BBB opening |
| Study Type | preclinical |
| Study Subtype | in vivo |
Publication
| Paper Linked | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427936/ |
|---|---|
| Paper Title | Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model |
| Paper Authors | Sulheim, Einar, Mørch, Yrr, Snipstad, Sofie, Borgos, Sven Even, Miletic, Hrvoje, Bjerkvig, Rolf, de Lange Davies, Catharina, Åslund, Andreas K.O. |
| Affiliation | Department of Physics, Norwegian University of Science and Technology (NTNU), Trondheim, Norway ; Department of Biotechnology and Nanomedicine, SINTEF AS, Trondheim Norway ; Department of Biotechnology and Nanomedicine, SINTEF AS, Trondheim Norway ; Cancer Clinic, St.Olav’s University Hospital, Trondheim Norway ; Department of Pathology, Haukeland University Hospital, Bergen, Norway ; Department of Biomedicine, University of Bergen, Norway ; Department of Oncology, Luxembourg Institute of Health, Luxembourg ; Stroke Unit, Department of internal medicine, St. Olav's University Hospital, Trondheim, Norway |
| Paper Journal | Nanotheranostics |
| Paper Year | 2019 |
| Paper Doi | https://doi.org/10.7150/ntno.31479 |
| Open Access | yes |
| Updated Year | 2023 |
Study Component
| Multi Modality Images | no |
|---|---|
| Imaging Modality | MRI |
| Imaging Sub Modality | T2W, DCE |
| Radiation | no |
| Imaging Coverage | brain |
| Imaging Target | anatomy, vascular permeability |
Dataset Information
| Institution | NTNU |
|---|---|
| Pi | Andreas K.O. Åslund |
| Country Of Institution | Norway |
| Imaging Facility | MR Core |
| Euro Bio Imaging Node | NORMOLIM |
| Country Of Imaging Facility | Norway |
In Vivo Experimental Parameters
| Number Of Groups | 4 |
|---|---|
| Types Of Groups | cab-NPMB and FUS; cab, empty NPMB and FUS; cab; saline control |
| Overall Sample Size | 15 |
| Disease Model | cancer |
| Organ Or Tissue | brain |
| Sample Size For Each Group | 3 for cab-NPMB and FUS; 4 for cab, empty NPMB and FUS; 4 for cab; 4 for saline control |
| Power Calculation | none |
| Inclusion Criteria | none |
| Exclusion Criteria | none |
| Randomization | yes mice were randomly divided into four groups |
| Blinding | no |
| Outcome Measures | tumor growth, cab accumulation using mass spectrometry, signal ratio of treated/non-treated hemisphere |
| Statistical Methods | Not stated |
| Species | Mice |
| Strain | NOD/SCID, Balb/c nudes |
| Immune Status | immunedeficient |
| Sex | female |
| Age | older than 8 weeks |
| Age At Start Experiment | older than 8 weeks |
| Age At Scanning Experiment S | older than 11 weeks, weekly scanning |
| Weight | About 20 g |
| Weight At Start Experiment | About 20 g |
| Weight At End Experiment | About 20 g |
| Source Of Animals | Janvier Labs |
Experimental Procedures
| Pharmacological Drug | Jevtana® (Cabazitaxel), and poly(2-ethyl butylcyanoacrylate) (PEBCA) NPs (cab-NPs, diameter 153 nm) and NP stabilized microbubbles (NPMBs, diamter > 1000 nm) (experimental) |
|---|---|
| Company | Sanofi-Aventis |
| Drug Dose | 10 |
| Volume | 0,05 |
| Site Route Of Administration | intravenous |
| Frequency Of Administration | two times, with a week apart |
| Vehicle Or Carrier Solution Formulation | saline |
| Blood Sampling | no |
| Surgical Procedures Including Sham Surgery | yes |
| Description Of The Surgical Procedure | Intracranial inoculation of glioma cells. The skin was sterilized by ethanol and a 1 cm sagittal incision was made to expose the bregma. A hole was drilled at the coordinates A +1, L -2 and V -3.5 mm in relation to bregma. 5 ?l cell suspension (200 000 cells) was aspirated into a 25 ?l Hamilton syringe (Model 1702 N). The syringe was mounted onto a stereotactic frame and inserted into the brain slowly for 4 mm and then retracted 0.5 mm, before the injection. The injection was performed over 3 minutes and 2 minutes later the syringe was slowly retracted. |
| Target Organ Tissue | brain |
| Pathogen Infection Intervention And Control | no |
| Analgesic Plan To Relieve Pain Suffering And Distress | yes |
| Analgesic Name | Marcain |
| Route | subcutaneous injection |
| Analgesic Dose | 1:5, 0.04 ml/20g |
| Anesthesia Type | gas |
| Duration | ~30 minutes |
| Anesthesia Drugs | Isoflurane |
| Anesthesia Dose | ~2% in 78% medical air/20% O2 |
| Euthanasia | yes |
| Method | cervical dislocation |
| Histology | yes |
| Tissues Collected Post Euthanasia | brain |
| Timing Of Collection | after the last scanning |
| Histological Procedure | formalin fixed |
| Name Of Reagent S | anti-P-gp antibody |
| Catalogue Number | EPR10364-57, Abcam |
| Frequency Of Imaging | weekly |
| Timing Of Imaging | three weeks after inoculation |
| Overall Scan Length | ~ 6 minutes (for tumour development evaluation) |
| Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule | yes |
| Contrast Agent Commercial Drug | Omniscan |
| Contrast Agent Chemical Drug | gadolinium |
| Route Of Administration | intravenous |
| Cell Line | P3, patient derived |
| Modified Cell Line | no |
| Cell Injection Route | intracranial |
| Number Of Cells | 200 000 cells |
| Housing Room | SPF |
| Dietary Intervention | no |
| Respiration Rate | only during scanning |
| Body Tempurature Etc | only during scanning |
| Food Intake Measured | no |
Image Acquisition
| Instrument Vendor | Bruker |
|---|---|
| Instrument Type | BioSpec 70/20 |
| Instrument Specifics | 7T |
| Raw Data | yes |
| Qa Qc | yes, annual QC |
Image Correlation
| Image Type | Primary image |
|---|---|
| Format Compression | DICOM, raw |
| Dimensions | 2D |
| Overall Number Of Images | T2-RARE for anatomy, FLASH to evaluate BBB-opening,3x FLASH acquired |
| Field Of View | 20mm x 20mm |
| Dimension Extents | 200 x 200 x 1mm |
| Size Description | 20mm x 20mm x 9mm |
| Pixel Voxel Size Description | 100um x 100 um x 1mm |
| Ai Enhanced Algorithm | no |
Analyzed Data
| Analysis Result Type | Numerical |
|---|---|
| Data Used For Analysis | volume measurements, ratio of signal from treated and untreated hemispheres |
| Analysis Method And Details | HOROS |
| Status | complete |
Ontology Terms
| Ncit Imaging | NCIT:C16809 |
|---|---|
| Ncit Imaging Submodality | NCIT:C180729,NCIT:C62665 |
| Doid | DOID:162 |
| Ncit Anatomy | NCIT:C12439 |
| Ncit Species | NCIT:C14238 |
| Ncit Strain | NCIT:C15167,NCIT:C15159,NCIT:C37357,NCIT:C14239 |
| Chebi Pharmaco | CHEBI:63584 |
| Chebi Anesthesia | CHEBI:6015 |
| Chebi Contrast Agent Commercial Name | CHEBI:31642 |
| Chebi Contrast Agent Chemical Name | CHEBI:31642 |